Home » Drug Information » New Medical Therapies™
August 1, 2011
Histogenics released results from a phase II trial of their NeoCart Autologous Cartilage Tissue Implant (ACTI). This randomized, controlled study enrolled 30 subjects with knee cartilage injury who received the NeoCart implant or underwent microfracture (MF) repair surgery. The results showed ACTI treatment using NeoCart led to statistically significant improvements in knee and general health outcomes scores by six months, at the primary endpoint of twelve months, and were then sustained for at least two years. NeoCart had a higher proportion of therapeutic responders in comparison to MF at one and two years.